The clinical trial is sponsored by the Chinese PLA General Hospital and focuses on the use of decitabine followed by donor lymphocyte infusion (DLI) in patients with relapsed acute myeloid leukemia (AML) post-allogeneic stem cell transplantation. Given the increasing incidence of AML and the limited treatment options available, this trial addresses a significant unmet medical need. The potential for decitabine to enhance the efficacy of adoptive T cell therapy could position it favorably in the competitive landscape of AML treatments. Market implications include potential partnerships or licensing opportunities for the sponsor, particularly if the trial demonstrates significant efficacy and safety. Diligence considerations should include the regulatory pathway for decitabine in this indication and the competitive profile of existing therapies.